Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Diabetes and Heart Failure

Trial Profile

Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Diabetes and Heart Failure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms EMBRACE-HF
  • Most Recent Events

    • 30 Mar 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
    • 30 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 14 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top